Farmas USA

Apuntame a esa visión, si te confudes ya no te confundes solo.

SPY, 2 meses......

Pues yo soy bajista short term

2 a 5% en nuestro sector XBI

2-3% en SPY

RGLS

y a la NOVENA semana se vió el verde ...

RDUS, reitero mi warning por bear flag de la semana pasada 

ACAD , contraviento y marea parece que a cerrar el gap que va ... 

HZNP, su ER en 2 semanas 

IBB XBI

Abstracts ASCO este miércoles

JMP: Titles to the ASCO abstracts will be released this Wednesday, April 25, and we hope there may be a positive surprise or two.

Se que llevas celgene. Por elliot la queda un buen rebote. Seguramente me suba a ella

Dynavax’s HEPLISAV-B ACIP recommendations published in the CDC’s MMWR

Apr. 23, 2018 7:28 AM ET|About:  Dynavax Technologies Corpo... (DVAX)|By:  Mamta Mayani, SA News Editor 

Dynavax Technologies (NASDAQ: DVAX)  announces that the Centers for Disease Control and Prevention (CDC) published the Advisory Committee of Immunization Practices’ Recommendations for the use of HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for adults in the US in the Morbidity and Mortality Weekly Report (MMWR) dated April 19.

Publication in the MMWR represents the final endorsement that many policies require before reimbursement. HEPLISAV-B was commercially launched in the U.S. in January.

https://seekingalpha.com/news/3347464-dynavax-s-heplisav-b-acip-recommendations-published-cdc-s-mmwr

MLNT

Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations

https://globenewswire.com/news-release/2018/04/23/1485323/0/en/Melinta-Therapeutics-Presents-Results-from-VABOMERE-TANGO-II-Trial-at-ECCMID-2018-Highlighting-Outcomes-in-Vulnerable-Patient-Populations.html